Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research III1 Apr 2014MP41-19 THREE-DIMENSIONAL MOLECULAR CHARACTERIZATION AND ISOLATION OF CIRCULATING TUMOR CELLS IN METASTATIC PROSTATE CANCER PATIENTS Tadeusz Kroczak, Julius Adebayo Awe, Adam Yan, Nidhi Shah, Alex Kuzyk, Jeff Saranchuk, Sabine Mai, and Darrel Drachenberg Tadeusz KroczakTadeusz Kroczak More articles by this author , Julius Adebayo AweJulius Adebayo Awe More articles by this author , Adam YanAdam Yan More articles by this author , Nidhi ShahNidhi Shah More articles by this author , Alex KuzykAlex Kuzyk More articles by this author , Jeff SaranchukJeff Saranchuk More articles by this author , Sabine MaiSabine Mai More articles by this author , and Darrel DrachenbergDarrel Drachenberg More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1236AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Circulating tumor cells (CTCs) are emerging as a promising bio-marker in prostate cancer screening and in monitoring of disease progression. In order to utilize CTCs clinically, an efficient and reliable method of CTC isolation must be developed. Upon isolation of CTCs, analysis of the three-dimensional (3D) nuclear organization of telomeres can be used to further profile and stratify prostate cancer patients. The relative aggressiveness of a tumor can be correlated to the degree of chromosomal instability seen within a given cell. We show that metastatic prostate cancer patients display CTCs and telomeric profiles that correlate to high-risk prostate cancer phenotypes. Methods CTCs from ten consecutive patients presenting with metastatic prostate cancer were isolated using the size based ScreenCell filtration technique. Cytokeration 8,18, 19 immunostaining and 3D quantative fluorescence in situ hybridization was performed on the isolated CTCs followed by 3D image acquisition using a Carl Zeiss AxioImager Z2 microscope. Quantitative image analysis with TeloviewTM and Teloscan were then preformed to obtain 3D telomere profiles and to identify the number of CTCs. Results Our data shows that CTCs are present in abundance and can be isolated in patients with metastatic prostate cancer. Furthermore, these CTCs have similar telomere profiles when comparing the following statistical parameters: percentage of cells with aggregates, average number of telomeres per cell, average number of aggregates per cell and average nuclear volume. Conclusions This proof of principle study shows for the first time that CTCs in metastatic prostate cancer patients can be reliably isolated and characterized by 3D nuclear telomere profiling using ScreenCell filters as well as presenting similar telomeric profiles. These findings show that prostate cancer CTCs and telomeric analysis have the potential to become a biomarker for tumor stage and progression. Our results could be used as positive controls when looking at less aggressive prostate cancer phenotypes. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e458 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Tadeusz Kroczak More articles by this author Julius Adebayo Awe More articles by this author Adam Yan More articles by this author Nidhi Shah More articles by this author Alex Kuzyk More articles by this author Jeff Saranchuk More articles by this author Sabine Mai More articles by this author Darrel Drachenberg More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call